Enovis Co. (NYSE:ENOV - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $37.18, but opened at $35.81. Enovis shares last traded at $35.07, with a volume of 101,103 shares trading hands.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price objective on shares of Enovis in a research note on Wednesday, April 2nd.
View Our Latest Stock Report on ENOV
Enovis Price Performance
The stock has a market cap of $1.81 billion, a P/E ratio of -14.53 and a beta of 1.86. The business has a 50-day simple moving average of $40.90 and a 200 day simple moving average of $43.09. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.
Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The firm had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. On average, analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.
Hedge Funds Weigh In On Enovis
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its stake in Enovis by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 66,668 shares of the company's stock valued at $2,870,000 after acquiring an additional 2,123 shares during the period. FMR LLC grew its position in Enovis by 20.5% in the 3rd quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares during the period. Benjamin Edwards Inc. increased its stake in Enovis by 34.9% during the 3rd quarter. Benjamin Edwards Inc. now owns 15,595 shares of the company's stock valued at $671,000 after purchasing an additional 4,035 shares in the last quarter. Centiva Capital LP acquired a new position in Enovis during the third quarter worth $326,000. Finally, Quantinno Capital Management LP lifted its stake in shares of Enovis by 363.8% in the third quarter. Quantinno Capital Management LP now owns 28,804 shares of the company's stock valued at $1,240,000 after buying an additional 22,593 shares in the last quarter. Institutional investors own 98.45% of the company's stock.
Enovis Company Profile
(
Get Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
See Also
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
